IO Biotech Net Cash Flow 2021-2025 | IOBT

IO Biotech net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

IO Biotech Net Cash Flow 2021-2025 | IOBT

IO Biotech net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.1B
Amgen (AMGN)$153.8B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$100.5B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$80.3B
CSL (CSLLY)$66.8B
Regeneron Pharmaceuticals (REGN)$61.4B
Alnylam Pharmaceuticals (ALNY)$59.3B
Argenex SE (ARGX)$43.1B
Insmed (INSM)$28.5B
BioNTech SE (BNTX)$24.5B
Royalty Pharma (RPRX)$20.8B
Biogen (BIIB)$19.4B
Genmab (GNMSF)$16.4B
Incyte (INCY)$16.3B
Genmab (GMAB)$16.1B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.5B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B